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Abstract
conventional wisdom in the pathogenesis of obesity and related cardiometabolic, malignant and neurodegenerative diseases 
focuses mainly on genetic predisposition and lifestyle (high caloric foods, sedentary lifestyle, smoking). The human genome 
project’s big promise was that it could improve our understanding of the pathogenesis and therapy of diseases. however, the 
genes have been found to account for only about 10% of diseases, and the remaining causes appear to be from environmental 
exposures, hence the exposure science emerges. note that molecular epidemiology and toxicology may be essential partners 
of exposure science. Indeed, Homo sapiens recens is exposed to an overwhelming number of chemical contaminants circulating 
every day in the air, water, food, and general environment. The body is a well-equipped entity with capabilities to excrete water-
soluble pollutants, but not as well-equipped to excrete some of the lipid-soluble xenobiotics. In the late 1990’s, according to 
the European Environmental agency more than 100 000 chemical compounds were registered in the European catalogue 
of commercialized chemical substances. here we present data that adipose tissue may be an important participant in the 
environmental molecular toxicology. The discovery of adipocyte-secreted leptin in 1994 was a paradigm shift event in the study 
of adipose tissue. It was applauded by scientific community and thus triggered a new direction in the evaluation of endocrine 
function of adipose tissue, that is, adipoendocrinology.  This is why the today’s adipose tissue is viewed not merely as a lipid 
storage, but also as a dynamic secretory – endocrine and paracrine – organ, synthesizing, storing, and releasing a dazzling 
number of signaling proteins collectively termed adipokines. numerous evidence demonstrates that the exposure to persistent 
organic pollutants (pOp) may contribute to the pathogenesis of obesity and its related diseases. noteworthy, these pollutants 
accumulate mainly in the adipose tissue. and xenobiotic-metabolizing cytochromes p450 (cyp) are expressed in adipose tissue, 
where cyp1a1 and cyp1b1 can bioactivate carcinogenic polycyclic aromatic hydrocarbons and xenoestrogens. altogether, the 
present review highlights an adipocentric approach in molecular toxicology. It is conceptualized as adipotoxicology, that is, the 
study of accumulation, metabolism, and release of xenobiotics in adipose tissue in health and disease. In effect, the adipose tis-
sue may be a new bridge between environment and health - let us call it a master in toxicology.
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The adipose tissue in the human body 
is there for the best, the bad, and the worse!
Charles Lapiere and Erik Maquoi 
(Exp Dermatol 2007; 16:67-70)
introduction
Homo sapiens recens seems to be the only species that expresses 
an obese phenotype (1), hence the term Homo obesus was re-
cently introduced (2). Current epidemiological data show a dra-
matic increase in obesity globally. Alarmingly, similar trends are 
also apparent in children. Overall, obesity and related diseases 
are a major personal and public health concern. 
The human genome project’s big promise was that it could 
improve our understanding of the pathogenesis and therapy of 
diseases. However, the genes have been found to account for 
only about 10% of diseases, and the remaining causes appear 
to be from environmental exposures. Indeed, today’s man is ex-
posed to an overwhelming number of chemical contaminants 
every day in our air, water, food, and general environment. The 
body is a well-equipped to excrete water soluble pollutants, but 
not as well-equipped to excrete some of the lipid-soluble ones. 
According to the European Environmental Agency in the late 
1990’s more than 100 000 chemical substances were registered 
in the European Catalogue of Commercialized Chemical Sub-
stances. However, less is known about late toxicity effects of the 
majority of these compounds. There is relatively enough toxico-
logical data for only 14% of these 100 000 substances to ensure 
their safety. Moreover, many fat-soluble chemicals tend to accu-
mulate in the body’s fatty tissues, where they may persist indefi-
nitely. Thus, over 300 foreign chemicals have been identified in 
human adipose tissue, brain and breast milk.
Interactions between foreign chemicals (xenobiotics) and liv-
ing systems occur in several  phases. The first is the exposure 
phase where the living organism is exposed to the chemical and 
which may or may not be followed by uptake of the chemical 
into the organism. In the next phase the chemical is distributed 
throughout the organism. After delivery of the chemical to vari-
ous parts of the organism, the next phase is metabolism medi-
ated by enzymes, where chemical changes may or may not oc-
cur. These phases are termed “toxicokinetics,” whereas the next 
phase is the toxicodynamic phase in which the chemical and its 
metabolites interact with constituents of the organism.  This se-
quence may then be followed by a phase in which pathological 
or functional changes occur
Environmental toxins interfere with glucose and cholesterol 
metabolism, as well as with adipokine secretion, and induce 
insulin resistance and cell proliferation, thus implicated in the 
pathogenesis of cardiometabolic and malignant diseases. Tox-
ins are related to the development of these diseases also through 
multiple other mechanisms, including inflammation, oxidative 
stress, mitochondrial injury, altered thyroid metabolism, and 
impairment of food behavior. 
Adipose tissue 
There are two main type of adipose tissue, white adipose tissue 
(WAT) and brown adipose tissue (BAT). Both are a dynamic 
assembly of adipocytes (fat cells), non-fat cells and extracel-
lular matrix components. At birth, the average-size infant has 
approximately 5 billion adipocytes, whereas - approximately 
80 billion in adult. Adding to them billions of stromal-vascular 
cells, makes the whole body WAT a major human’s secretory or-
gan. In humans, adipose tissue (hereafter to be considered WAT) 
is partitioned into two large depots (subcutaneous and visceral) 
and many small depots associated with heart, blood vessels, ma-
jor lymph nodes, pancreas, prostate gland, ovaries, and thymus. 
Accordingly, two major subfields of adipobiology have emerged, 
adipoendocrinology (studying the endocrine activity of adipose 
tissue) and adipoparacrinology (studying the paracrine activity 
of adipose tissue); both dealing with the pathogenesis of obesity-
related diseases (3-16). 
The so-called “brite” (brown-in-white) adipocytes were rec-
ognized recently. These are of particular medical relevance, be-
cause current data indicate that higher amounts of brown adi-
pose tissue are positively associated with resistance to obesity 
and related diseases, and that “browning” of the adipose tissue 
may be of therapeutic significance for these disorders (17,18). 
Conventional association of the word “adipose tissue” usually 
refers to lipid and energy storage (white adipose tissue) and to 
thermogenesis (brown and “brite” adipose tissue). In white adi-
pose tissue, however, it is much more than that. 
In 1987, adipsin, a circulating serine protease of complement 
system, was found as the first discovered endocrine product of 
adipocytes. However, it was since 1994 when leptin, a circulat-
ing cytokine, was discovered which has been triggering fur-
ther studies on the secretory potential of adipose tissue. Recent 
genomics, proteomics and microarray methodologies have dra-
matically increased the number of adipose tissue-secreted mol-
ecules (see Renes in this volume of Adipobiology), conceptually 
termed adipokines (3,6).
Taken together, these and other studies have shifted the para-
digm of adipose tissue from simple energy storage to the body’s 
major endocrine and paracrine organ.
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Adipose tissue as a safety or harmful xenobiotics storage 
site
Safety xenobiotics site
In case of acute poisoning with different xenobiotics adipose tis-
sue contributes to body detoxication and survival. Body distri-
bution of different xenobiotics largely depends on their solubil-
ity in lipids or water. In this respect the quantity of a particular 
xenobiotic in adipose tissue will depend from its n-octanol:water 
partition coefficient and the ratio of lipid in adipose tissue and 
blood. For human this last ratio is around 200 for most environ-
mental pollutants (19). The uptake of polychlorinated biphenyls 
(PCB) was directly linked to the triglyceride content of adipo-
cytes and did not depend on the presence of caveolin-1 (20). This 
data set adipose tissue as the main body site for xenobiotics dis-
tribution. In a person who is obese, up to 50% of his/her weight 
is lipid. As a comparison, only 10% fat will be found in someone 
who is starving. Hence a higher dose of a particularly lipophilic 
drug would be needed for someone who is overweight. In some 
cases, storage of lipophilic chemicals in adipose tissues appears 
to sequester the chemicals from their toxicity target tissue, and 
thus obesity may be protective (21). There are few data on the 
distribution of war nerve agents in animal adipose tissue. Thus 
after whole body vapor exposure of minipigs to sarin only trace 
amount could be found in adipose tissue (22). 
Adipose tissue contributes considerably to overall body xenobi-
otics detoxication 
A set of xenobiotic-metabolizing enzymes are found in adipose 
tissue. These include paraoxonases (human PON3) (23), car-
boxylesterases (24) and some isozymes of UDP-glucuronosyl-
transferases (25,26). Several cytochrome p450 (CYP) isozymes 
are also expressed in adipocytes and their activity was induced 
by typical lipophilic inducers: CYP 1B1 (metabolism of steroid 
hormones, induced by dioxin and highly expressed also in breast 
cancer cells); CYP 2U1 (involved in fatty acids metabolism) (27); 
CYP 1A1 (induced by β-naphthoflavone); CYP 2B’s and CYP 
3A’s (induced by phenobarbital and dexamethasone); CYP 2E1 
(induced by fasting condition) (28). Aromatase (CYP19) is also 
expressed in human adipose tissue and play crucial role in estro-
gen biosynthesis in postmenopausal women and breast cancer 
development (29). Downregulation of male-specific cytochrome 
P450 aromatase by profenofos was found (30).
Harmful xenobiotics site 
Adipose tissue is preferential depot of various lipophilic envi-
ronmental pollutants, especially of those which are resistant to 
biological and chemical degradation, the so-called persistent or-
ganic pollutants (POP); these are also accumulated in high levels 
of the food chain. Thus food, especially fatty fish, meat and milk 
products, is the main source of human exposure to POP. The 
variability of the stored amount of particular POP in adipose 
tissue depends on dietary exposure. It is determined by adipose 
size and by changes in adiposity. Weight loss results in an in-
crease of their concentration in reduced adipose tissue and their 
elimination rate is consequently decreased significantly with in-
creasing body fat content. 
Examples of environmental contaminants are trichloroethyl-
ene (31), alkylphenols (32), dioxins (33), polycyclic aromatic hy-
drocarbons (PAH) and synthetic musk compounds (SMC) (34). 
Recent study of Lind et al. (35) demonstrated that the body dis-
tribution of highly chlorinated PCB was related to the VAT/SAT 
ratio. In large scale epidemiological survey in women was shown 
that circulating concentrations of mono-isobutyl phthalate were 
positively related to increased fat amount in the subcutaneous 
abdominal region (36). 
Studies show that adipose tissue stored xenobiotics can be mo-
bilized in persons under the influences of heat exposure (rapid 
weight reduction in athletes), exercise, emotional stress, illness 
and the overnight fast during sleep. Thus they could cause some 
difficulty understandable pathological reactions. Some factors 
that could influence the response are: severity of bioaccumula-
tion, individual sensitivities, genetic predisposition, diet and the 
age of patient. In some cases with organophosphate poisoning 
the conventional treatment caused a recurrence of symptoms 
attributed to mobilization of the organophosphate stored in adi-
pose tissue (37). For instance, a case of fenitrothion poisoning 
promptly treated by conventional treatment caused a recurrence 
of symptoms attributed to mobilization of the organophosphate 
stored in adipose tissue (38). 
When studying the reasons of sever neurotoxicity in veterans 
from Vietnam war, several investigators found out that it could 
not be attributed to defoliant exposure (so called Agent Orange) 
because the average level of 2,3,7,8-TCDD in their adipose tis-
sue was not significantly different from that of the non-Vietnam 
veterans or the civilians (39). 
Altogether, the accumulation and metabolism of environ-
mental toxins in adipose tissue was implicated in the pathogen-
esis of cardiometabolic and malignant diseases. Thus, a concept 
of adipotoxicology and adipose tissue as “toxicrine” organ has 
emerged (40). 
What is that environmental obesogens?
Nowadays, the number of environmental toxicants showed as 
potential obesogens continuously increases. In fact, Grun and 
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Blumberg coined the term obesogen, in 2006 (41). These authors 
discovered that tin-based compounds known as organotins pre-
disposed laboratory mice to gain weight. Obesogens as well 
as endocrine disruptors are defined functionally as chemicals 
(natural, pharmaceutical, or xenobiotic) that promote obesity by 
increasing the number and/or size of adipocytes or fat storage 
into the existing adipocytes (42-46).
The process by which adipose cells are derived from a mes-
enchymal pre-adipocyte involves an orchestrated series of dif-
ferentiation steps mediated by a cascade of specific transcription 
factors. Of particular importance is the activation of the nuclear 
receptor (NR) peroxisome proliferator-activated receptor-gam-
ma (PPARγ) that heterodimers with another NR, the retinoic X 
receptor (RXR) and binds to specific promoter region of target 
genes of the pre-adipocyte and regulates its expression (47-49). 
By this way the PPARγ and RXR receptor dimer is involved in 
the transcriptional control of energy, lipid, and glucose homeo-
stasis and is the main cellular target of environmental obesogens 
(50).
Examples of potential environmental obesogens acting main-
ly through activation of retinoid X receptors (RXRα,β, and γ) 
and PPARγ include: 
Organotins (biocides, heat stabilisers and chemical catalysts 
(41,42,51) are potent nanomolar agonist ligands for the NRs 
RXR and PPARγ. In vitro and in vivo studies on animals showed 
that they could activate RXR/PPARγ-dependent pre-adipocytes 
gene network and regulate adipocytes number, size and func-
tion. Polychlorinated biphenyls (PCB) (52); Phthalates (53-
55); Bisphenol A (BPA) – widely used plasticizer (56) with 
potent estrogen activity (57); Polybrominated diphenyl ether 
(PBDE) and halogenated derivatives of BPA - flame-retardants 
(58,59); Dichloro-diphenyl-trichloroethane (DDT) (60); Bu-
tylparaben – antimicrobial preservative in cosmetics and fla-
voring additive in food (61); Phenylsulfamide family of fun-
gicides (Tolylfluanid), used in antifouling paints as well as on 
fruit crops in agriculture (62); Perfluorooctanoic acid (PFOA) 
– surfactant with large industrial usage (63,64); Heavy metals – 
arsenite (65). Drugs – diethylstilbestrol (a synthetic form of es-
trogen)(66), olanzapine (atypical anti-psychotic drug), selective 
serotonin reuptake inhibitors, tricyclic antidepressants, the thia-
zolidinedione anti-diabetic drug rosiglitazone (67). In clinical 
trials the beneficial metabolic (anti-diabetic) effects of angioten-
sin type 1 receptor blocker Losartan was shown to be due to its 
active metabolite EXP3174 acting as partial PPARγ agonist (68). 
The body weight loss observed after the use of anticancer drug 
adriamycin was shown to be due to inhibition of adipogenesis by 
down-regulation the expression of PPARγ (69).
Xenobiotics and secretion of adipokines
All PPARg-activating chemicals inducing adipocyte differentia-
tion were able to affect leptin, adiponectin, and resistin release 
during terminal differentiation of adipocytes, and of these the 
majority also induced lipid accumulation. For example, bis-
phenol A (BPA), at environmentally relevant doses, inhibit adi-
ponectin and stimulate the release of inflammatory adipokines 
such as interleukin-6 (IL-6) and tumor necrosis factor-alpha 
(TNF-a) (70), including from breast adipose and abdominal 
subcutaneous adipose explants (71). Exposure to p,p’-dichlo-
rodiphenyldichloroethylene (DDE) significantly increased the 
release of leptin, resistin, and adiponectin from mature adipo-
cytes (72). Neonatal parathion exposure uncoupled serum lep-
tin levels from their dependence on body weight, suppressed 
adiponectin and elevated TNF-α in adipose tissue (73). Long-
term and low-concentration human body exposure to triclosan, 
an antimicrobial agent used in some toothpastes and shampoos, 
can inhibits adipocyte differentiation of human mesenchymal 
stem cells (74). Aluminum toxicity leads to an increased iron 
(Fe) concentration in the serum of the body. Note that high 
blood Fe levels causes the liver and adipose tissue to secrete hep-
cidin, a Fe homeostasis regulator that signals the decrease in Fe 
absorption by enterocytes as well as a decrease in Fe release from 
cellular stores such as red blood cells thus induced anemia (75).
Environmental contaminants and prenatal and perinatal 
metabolic programming
The Environmental Working Group study found the average 
newborn has 287 chemicals in the umbilical cord blood, 217 of 
which are neurotoxic (76). Thus pregnant women with chronic 
exposure to environmental toxins are with potential risk to have 
obesity generation in later life (77). For example organotin ex-
posure during prenatal adipose tissue development leads to an 
increased number of preadipocytes from immortal stem cells. 
This could correspondingly increase the steady state number of 
adipocytes in the adult, which could favor the development of 
obesity over time (78,79). Same action was find out in animals 
for DDT and other organochlorine compounds (60,80,81), bi-
sphenol A (56,82,83), tributyltin (84), organophosphate pesti-
cides (85), nicotine from maternal smoking (86) and, in general, 
POP (87,88). The main conclusion from these studies is that the 
adipocyte number is refractory to change once established in the 
prenatal period of developmental programming.
On important conclusion from already known facts is that 
although the effects of obesogens of early-life exposure are ir-
reversible such people can reduce later harmful health effects by 
controlling their life style eating organic, drinking filter water, 
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minimize plastic in their life. As Dr Thayer stressed in the recent 
Workshop organized by National Institute of Environmental 
Health Sciences (USA) and dedicated to the problems of “Envi-
ronmental Chemicals in Diabetes and Obesity”: “We were sur-
prised at the number of chemicals that seem to be interacting 
with signaling pathways involved in weight regulation.” She adds 
that evidence also suggests these same compounds are linked to 
diabetes and metabolic syndrome, “an understudied but natural 
research direction that brings together the obesity and diabetes 
issues” (89).
Conclusion 
She had never forgotten that, if you drink much from
a bottle marked “poison”,  it is almost certain 
to disagree with you, sooner or later.
From Alice’s Adventures in Wonderland, 
by Lewis Carroll
Toxicology may be regarded as the science of poisons. We have 
provided evidence that adipose tissue may be an important par-
ticipant in the environmental molecular toxicology. And con-
ceptualized that as adipotoxicology. “Adipotoxicology” connotes 
the study of accumulation, metabolism, and release of xenobi-
otics in adipose tissue in health and disease. Accordingly, the 
need for human biomonitoring of xenobiotics accumulation in 
adipose tissue is mandatory. In effect, the adipose tissue may be 
a new bridge between environment and health - let us call it a 
master in toxicology. This holds promise in better management 
of the life of Homo sapiens obesus.
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